Login Register Cart 0
Generic placeholder image

Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 1871-5230
ISSN (Online): 1875-614X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

A New Moisturiser Improves DNCB-induced Atopic Dermatitis-like Symptoms and Restores Skin Barrier Function in BALB/c Mice

Author(s): Christelle Foucher*, Jean-François Bisson, Martine Guy, Hao Trong Nguyen, Sophie Hidalgo, Julie Colin, Tu Nguyen Anh Tran and Thao Thi Phuong Vu

Volume 22, Issue 1, 2023

Published on: 13 July, 2023

Page: [49 - 57] Pages: 9

DOI: 10.2174/1871523022666230529150043

Price: $65

Abstract

Introduction: Atopic dermatitis (AD) is a chronic, inflammatory skin disorder with eczematous and pruritic lesions. Topical moisturisers and either topical corticosteroids or calcineurin inhibitors are usually recommended. Restoring the skin barrier function alleviates AD symptoms.

Objective: To evaluate the efficacy of a new moisturiser compared to commercially available products in an AD murine model.

Methods: Experimental AD was induced with topical applications of 2,4-DiNitroChloroBenzene (DNCB) on the shaved back skin of BALB/c mice from Day 1 to Day 38. Mice were randomized to either Vehicle/-, DNCB/-, or DNCB/Eczekalm (test product), DNCB/Atopiclair®, or DNCB/Lipikar (reference products) groups. Once daily application of either Eczekalm or Atopiclair® or Lipikar on the AD lesion was performed from Day 32 to Day 38. The AD severity index (ADSI) and animal behaviour were monitored throughout the study. The trans-epidermal water loss (TEWL) was measured on the sacrifice day (Day 39).

Results: At Day39, ADSI in the DNCB/Eczekalm, DNCB/Lipikar, and DNCB/Atopiclair® groups were significantly lower by -70%, -68%, and -57%, respectively, as compared to DNCB/- (p < 0.001). No sign of erythema was observed in the DNCB/Eczekalm group. Mean scores of skin oedema, excoriation, and dryness in the DNCB/Eczekalm, DNCB/Lipikar, and DNCB/Atopiclair® groups were significantly lower than in the DNCB/-. No significant difference was observed between DNCB/Eczekalm and DNCB/Lipikar groups. Mean TEWL in DNCB/Eczekalm group was significantly lower than the ones of DNCB/Atopiclair® (-43%, p < 0.001) and DNCB/Lipikar (-15%, p < 0.05).

Conclusion: Eczekalm treatment significantly reduced the inflammatory effects due to AD and itching episodes and restored the skin barrier function.

« Previous Next »
Graphical Abstract

[1]
Fishbein, A.B.; Silverberg, J.I.; Wilson, E.J.; Ong, P.Y. Update on Atopic dermatitis: Diagnosis, Severity assessment, and treatment selection. J. Allergy Clin. Immunol. Pract., 2020, 8(1), 91-101.
[http://dx.doi.org/10.1016/j.jaip.2019.06.044] [PMID: 31474543]
[2]
Drucker, A.M.; Wang, A.R.; Li, W.Q.; Sevetson, E.; Block, J.K.; Qureshi, A.A. The burden of atopic dermatitis: Summary of a Report for the National Eczema Association. J. Invest. Dermatol., 2017, 137(1), 26-30.
[http://dx.doi.org/10.1016/j.jid.2016.07.012] [PMID: 27616422]
[3]
Furue, M.; Chiba, T.; Tsuji, G.; Ulzii, D.; Kido-Nakahara, M.; Nakahara, T.; Kadono, T. Atopic dermatitis: Immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. Allergol. Int., 2017, 66(3), 398-403.
[http://dx.doi.org/10.1016/j.alit.2016.12.002] [PMID: 28057434]
[4]
Kim, J.; Kim, B.E.; Leung, D.Y.M. Pathophysiology of atopic dermatitis: Clinical implications. Allergy Asthma Proc., 2019, 40(2), 84-92.
[http://dx.doi.org/10.2500/aap.2019.40.4202] [PMID: 30819278]
[5]
Luger, T.; Amagai, M.; Dreno, B.; Dagnelie, M.A.; Liao, W.; Kabashima, K.; Schikowski, T.; Proksch, E.; Elias, P.M.; Simon, M.; Simpson, E.; Grinich, E.; Schmuth, M. Atopic dermatitis: Role of the skin barrier, environment, microbiome, and therapeutic agents. J. Dermatol. Sci., 2021, 102(3), 142-157.
[http://dx.doi.org/10.1016/j.jdermsci.2021.04.007] [PMID: 34116898]
[6]
Bertino, L.; Guarneri, F.; Cannavò, S.P.; Casciaro, M.; Pioggia, G.; Gangemi, S. Oxidative Stress and atopic dermatitis. Antioxidants, 2020, 9(3), 196.
[http://dx.doi.org/10.3390/antiox9030196] [PMID: 32111015]
[7]
Kwatra, S.G.; Misery, L.; Clibborn, C.; Steinhoff, M. Molecular and cellular mechanisms of itch and pain in atopic dermatitis and implications for novel therapeutics. Clin. Transl. Immunology, 2022, 11(5), e1390.
[http://dx.doi.org/10.1002/cti2.1390] [PMID: 35582626]
[8]
Trier, A.M.; Kim, B.S. Cytokine modulation of atopic itch. Curr. Opin. Immunol., 2018, 54, 7-12.
[http://dx.doi.org/10.1016/j.coi.2018.05.005] [PMID: 29935376]
[9]
Eichenfield, L.F.; Tom, W.L.; Berger, T.G.; Krol, A.; Paller, A.S.; Schwarzenberger, K.; Bergman, J.N.; Chamlin, S.L.; Cohen, D.E.; Cooper, K.D.; Cordoro, K.M.; Davis, D.M.; Feldman, S.R.; Hanifin, J.M.; Margolis, D.J.; Silverman, R.A.; Simpson, E.L.; Williams, H.C.; Elmets, C.A.; Block, J.; Harrod, C.G.; Begolka, W.S.; Sidbury, R. Guidelines of care for the management of atopic dermatitis. J. Am. Acad. Dermatol., 2014, 71(1), 116-132.
[http://dx.doi.org/10.1016/j.jaad.2014.03.023] [PMID: 24813302]
[10]
Newsom, M.; Bashyam, A.M.; Balogh, E.A.; Feldman, S.R.; Strowd, L.C. New and emerging systemic treatments for atopic dermatitis. Drugs, 2020, 80(11), 1041-1052.
[http://dx.doi.org/10.1007/s40265-020-01335-7] [PMID: 32519223]
[11]
Kang, S.Y.; Um, J.Y.; Chung, B.Y.; Lee, S.Y.; Park, J.S.; Kim, J.C.; Park, C.W.; Kim, H.O. Moisturizer in Patients with inflammatory skin diseases. Medicina, 2022, 58(7), 888.
[http://dx.doi.org/10.3390/medicina58070888] [PMID: 35888607]
[12]
Choi, Y.Y.; Kim, M.H.; Lee, H.; Ahn, K.S.; Um, J.Y.; Lee, S.; Kim, J.; Yang, W.M. Cynanchum atratum inhibits the development of atopic dermatitis in 2,4-dinitrochlorobenzene-induced mice. Biomed. Pharmacother., 2017, 90, 321-327.
[http://dx.doi.org/10.1016/j.biopha.2017.03.065] [PMID: 28365521]
[13]
Jin, H.; He, R.; Oyoshi, M.; Geha, R.S. Animal models of atopic dermatitis. J. Invest. Dermatol., 2009, 129(1), 31-40.
[http://dx.doi.org/10.1038/jid.2008.106] [PMID: 19078986]
[14]
Kim, J.; Lee, J.; Shin, S.; Cho, A.; Heo, Y. Molecular mechanism of atopic dermatitis induction following sensitization and challenge with 2,4-Dinitrochlorobenzene in mouse skin tissue. Toxicol. Res., 2018, 34(1), 7-12.
[http://dx.doi.org/10.5487/TR.2018.34.1.007] [PMID: 29371996]
[15]
Hong, S.; Lee, B.; Kim, J.H.; Kim, E.Y.; Kim, M.; Kwon, B.; Cho, H.R.; Sohn, Y.; Jung, H.S. Solanum nigrum Linne improves DNCB induced atopic dermatitis like skin disease in BALB/c mice. Mol. Med. Rep., 2020, 22(4), 2878-2886.
[http://dx.doi.org/10.3892/mmr.2020.11381] [PMID: 32945415]
[16]
Directive 2010/63/EU of the european parliament and of the council of 22 September 2010 on the protection of animals used for scientific purposes. 2020.
[17]
Buchanan, K.L.; de Perera, T.B.; Carere, C. Guidelines for the treatment of animals in behavioural research and teaching. Anim. Behav., 2012, 83(1), 301-309.
[http://dx.doi.org/10.1016/j.anbehav.2011.10.031]
[18]
Guide to the care and use of experimental animals. 2003. Available From: https://ccac.ca/Documents/Standards/Guidelines/Experimental_Animals_Vol1.pd
[19]
Hou, D.D.; Di, Z.H.; Qi, R.Q.; Wang, H.X.; Zheng, S.; Hong, Y.X.; Guo, H.; Chen, H.D.; Gao, X.H. Sea Buckthorn (Hippophaë rhamnoides L.) oil improves atopic dermatitis-like skin lesions via inhibition of NF-ƙB and STAT1 activation. Skin Pharmacol. Physiol., 2017, 30(5), 268-276.
[http://dx.doi.org/10.1159/000479528] [PMID: 28873377]
[20]
Kim, K.H.; Choung, S.Y. Oral administration of Vaccinium uliginosum L. extract alleviates DNCB-induced atopic dermatitis in NC/Nga mice. J. Med. Food, 2014, 17(12), 1350-1360.
[http://dx.doi.org/10.1089/jmf.2013.3053] [PMID: 25260029]
[21]
Yoon, H.J.; Jang, M.S.; Kim, H.W.; Song, D.U.; Nam, K.I.; Bae, C.S.; Kim, S.J.; Lee, S.R.; Ku, C.S.; Jang, D.I.; Ahn, B.W. Protective effect of diet supplemented with rice prolamin extract against DNCB-induced atopic dermatitis in BALB/c mice. BMC Complement. Altern. Med., 2015, 15(1), 353.
[http://dx.doi.org/10.1186/s12906-015-0892-0] [PMID: 26467986]
[22]
Seibenhener, M.L.; Wooten, M.C. Use of the open field maze to measure locomotor and anxiety-like behavior in mice. J. Vis. Exp., 2015, 96(96), e52434.
[PMID: 25742564]
[23]
Greco, L.; Ullo, S.; Rigano, L.; Fontana, M.; Berardesca, E.; Cameli, N. Evaluation of the filming and protective properties of a new trehalose and ceramides based ingredient. Cosmetics, 2019, 6(4), 62.
[http://dx.doi.org/10.3390/cosmetics6040062]
[24]
Greco, L.; Ullo, S.; Rigano, L.; Fontana, M.; Berardesca, E. Evaluation of the soothing and protective properties of a lignin hydrolysate. Cosmetics, 2019, 6(3), 38.
[http://dx.doi.org/10.3390/cosmetics6030038]
[25]
Chan, C.C.; Liou, C.J.; Xu, P.Y.; Shen, J.J.; Kuo, M.L.; Len, W.B.; Chang, L.E.; Huang, W.C. Effect of dehydroepiandrosterone on atopic dermatitis-like skin lesions induced by 1-chloro-2,4-dinitrobenzene in mouse. J. Dermatol. Sci., 2013, 72(2), 149-157.
[http://dx.doi.org/10.1016/j.jdermsci.2013.06.015] [PMID: 23891346]
[26]
Hong, S.; Ku, J.; Kim, H.; Lee, S.; Lim, Y.; Seo, H.; Shin, Y.; Ko, S.G. Oral administration of Cervus nippon mantchuricus extract suppresses 2,4-dinitrochlorobenzene-induced atopic dermatitis in BALB/c mice and inflammatory effects in mast cells. Int. J. Mol. Med., 2018, 42(5), 2961-2971.
[http://dx.doi.org/10.3892/ijmm.2018.3856] [PMID: 30226556]
[27]
Ku, J.M.; Hong, S.H.; Kim, H.I.; Seo, H.S.; Shin, Y.C.; Ko, S.G. Effects of Angelicae dahuricae radix on 2,4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions in mice model. BMC Complement. Altern. Med., 2017, 17(1), 98.
[http://dx.doi.org/10.1186/s12906-017-1584-8] [PMID: 28173791]
[28]
Yeo, H.; Lee, Y.H.; Koh, D.; Lim, Y.; Shin, S.Y. Chrysin inhibits NF-ƙB-dependent CCL5 transcription by targeting IƙB kinase in the atopic dermatitis-like inflammatory microenvironment. Int. J. Mol. Sci., 2020, 21(19), 7348.
[http://dx.doi.org/10.3390/ijms21197348] [PMID: 33027922]
[29]
Maurya, A.; Singh, M.; Dubey, V.; Srivastava, S.; Luqman, S.; Bawankule, D. α-(-)-bisabolol reduces pro-inflammatory cytokine production and ameliorates skin inflammation. Curr. Pharm. Biotechnol., 2014, 15(2), 173-181.
[http://dx.doi.org/10.2174/1389201015666140528152946] [PMID: 24894548]
[30]
Teo, C.W.L.; Tay, S.H.Y.; Tey, H.L.; Ung, Y.W.; Yap, W.N. Vitamin E in Atopic Dermatitis: From preclinical to clinical studies. Dermatology, 2021, 237(4), 553-564.
[http://dx.doi.org/10.1159/000510653] [PMID: 33070130]
[31]
Kim, S.H.; Seong, G.S.; Choung, S.Y. Fermented Morinda citrifolia (Noni) Alleviates DNCB-Induced Atopic Dermatitis in NC/Nga Mice through Modulating Immune Balance and Skin Barrier Function. Nutrients, 2020, 12(1), 249.
[http://dx.doi.org/10.3390/nu12010249] [PMID: 31963703]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy